Shares of WAVE Life Sciences WVE remained unaffected after the company reported Q4 results.
Quarterly Results
Earnings per share were up 64.24% year over year to ($0.59), which beat the estimate of ($0.61).
Revenue of $9,439,000 higher by 293.29% from the same period last year, which missed the estimate of $9,750,000.
Looking Ahead
WAVE Life Sciences hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Mar 04, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/d3y3ewzq
Recent Stock Performance
Company's 52-week high was at $19.98
Company's 52-week low was at $6.61
Price action over last quarter: Up 38.01%
Company Overview
WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
